A Phase 2 interventional study of VTX2735 and VTX2735 in Cryopyrin Associated Periodic Syndrome, sponsored by Zomagen Biosciences Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by Zomagen Biosciences Ltd. · Phase 2, Interventional, and Treatment
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B.
The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.
34 studies on the registry are indexed under Cryopyrin-Associated Periodic Syndromes; 5 are open to participants now.
This study's enrollment of 7 is below the median of 19 across 25 interventional studies indexed under Cryopyrin-Associated Periodic Syndromes.
Browse Cryopyrin-Associated Periodic Syndromes studies →Zomagen Biosciences Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: VTX2735
Drug: VTX2735
Dose A
Dose B
Safety and Tolerability of VTX2735
Incidence and severity of treatment-emergent adverse events (TEAE), serious adverse events (SAE), and discontinuation due to adverse events
Time frame: From the initial administration of VTX2735 through study completion, up to 10 weeks
Mean change in the mean key symptom score (KSS) derived from the Daily Health Assessment Form, Second Generation (DHAF2) from baseline
Assess the change from baseline in disease activity using DHAF2 and KSS.
Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28
Achievement of 30%, 50%, or 75% improvement in mean KSS from baseline
Proportion of patients achieving 30%, 50%, or 75% improvement from baseline in disease activity using DHAF2 and KSS.
Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28
Number of days when the daily KSS is >3
Number of multi-system disease flare days as defined by KSS
Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28
Number of days when any single DHAF2 symptom score is >3
Number of single system disease flare days as defined by KSS
Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28
Maximum severity of any symptom score on DHAF2
Maximum single DHAF2 symptom score
Time frame: From Day 1 to completion of treatment with VTX2735, up to Day 28
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cryopyrin-Associated Periodic Syndromes→
Zomagen Biosciences Ltd.